Neil Cowen, MS, PhD, MBA

SVP, Drug Development
Soleno Therapeutics

Poster(s):

• (147) Expected vs observed mortality rates, expressed as number needed to treat, from a Phase 3 clinical trial program of patients with hyperphagia and Prader-Willi Syndrome treated with diazoxide choline extended release (DCCR)
  Wednesday, October 29, 2025